@article {7878,
	title = {Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study},
	journal = {Cancer Chemotherapy and Pharmacology},
	volume = {62},
	year = {2008},
	note = {Cited By :11Export Date: 21 February 2017},
	month = {2008},
	pages = {277 - 284},
	abstract = {Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3\% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. Methods: This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m2 followed by irinotecan 160 mg/m2 administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. Results: Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16\%). In intent-to-treat analysis the tumor response rate was 13\% (95\% CI = 4.8-25.7\%) and 12 patients (27\%, 95\%CI 13.9-40.4\%) had at least 4 months{\textquoteright} duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40\% of patients alive at 1 year. Conclusions: The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP. {\textcopyright} 2007 Springer-Verlag.},
	keywords = {Chemotherapy, Irinotecan, Oxaliplatin, Phase-II, Trial, Unknown-primary-carcinoma},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-43749089186\&doi=10.1007\%2fs00280-007-0604-7\&partnerID=40\&md5=a2369adf4a179075d2ee5cc945bd94e5},
	author = {Briasoulis, E. and Fountzilas, G. and Bamias, A. and Dimopoulos, M.A. and Xiros, N. and Aravantinos, G. and Samantas, E. and Kalofonos, H. and Makatsoris, T. and Mylonakis, N. and Papakostas, P. and Skarlos, D. and Varthalitis, I. and N. Pavlidis}
}
